Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
about
Current concepts in diagnosis and treatment of chronic lymphocytic leukemiaChronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing OncologistManagement of elderly and unfit patients with chronic lymphocytic leukemia.Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocationPredicting survival in chronic lymphocytic leukemia.Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a reviewChoosing first-line therapy for chronic lymphocytic leukemia.Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial.Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia.Role of ofatumumab in treatment of chronic lymphocytic leukemiaFludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemiaβ2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaChronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based studyPrognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.Targeting inflammatory pathways in chronic lymphocytic leukemia.Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Molecular pathogenesis of CLL and its evolution.Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia.Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia
P2860
Q26770471-2B50AF60-75A7-4316-93BD-DE4E58E7B73AQ26775986-0DC616BD-2DEB-4A0C-A29B-985D1197B09BQ30243914-E9F438A8-11A5-4389-B449-AB723FAE38B1Q33396222-7648AE96-8279-4377-9DBD-D29C9250252CQ33409459-5DDB7455-0761-4AF4-991E-83C80BD7A933Q34166551-269C95CC-46A7-43A4-83C2-03D4BB3ACBD7Q34257190-07690850-5C45-4670-9615-3238BBC4710AQ34348572-39F0C7C2-D023-4FC8-BA08-6DCA01D2F761Q35124844-B9B6A5AE-8E4D-443E-9C23-3A6A50699008Q35265963-E5AE2678-3A82-4104-B967-3EC54AED4405Q35461949-1AE602D9-6E44-46FF-837F-2086BA7BB322Q35683837-B247809A-E01A-44FE-85F2-A8535ADAB23EQ35806293-8F664863-0561-4C8A-8316-E241A60A5F1EQ35814897-F7170FDC-6823-456E-942A-8A83DDF53BCDQ36743899-4EFB07F0-AF1D-4AC7-96DB-617CCFB46777Q36826893-12B477AB-FCBC-4A87-8257-6B50E216E14EQ36925185-95DF9104-3D1D-4E4E-9492-6CFC6B6D57C1Q37185719-92554D2E-B7AA-47F1-8E43-73F4E4A5F7A8Q37188389-BFCBB912-ADAE-4C6E-851D-6250BCBA8FC4Q37351312-41991BE4-4366-4CC2-BE91-54BD366A1F66Q37975154-E87608FB-FAD2-476B-AAD1-582FC88E297FQ38335695-3F179247-2C5A-4C34-9BE4-6C0EB64A9409Q38537523-F39FB951-3C60-4134-B675-2CB379DF1017Q40291708-7BB5A874-344D-4D9A-8E98-24D69C44B542Q42593100-1C23C592-1E49-484D-B798-9FDE9F22C282Q44078664-1ACE4F88-1327-4273-B21E-8778A75B7047Q45806334-09D4ECD7-7519-4A1A-B2AE-7E7CAE2B4EF1Q46130198-ACD7F423-7AB4-4C23-A022-98565547E98EQ50889970-5AA80563-0BE3-49EF-9F67-FB7D7AE19FBCQ58436696-7CBF2772-F643-431D-BA4F-4055E39E41B4
P2860
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Characteristics associated wit ...... leukemia at initial treatment.
@en
type
label
Characteristics associated wit ...... leukemia at initial treatment.
@en
prefLabel
Characteristics associated wit ...... leukemia at initial treatment.
@en
P2093
P2860
P50
P356
P1476
Characteristics associated wit ...... leukemia at initial treatment.
@en
P2093
Charles Koller
Deborah Thomas
Jan Burger
Kim-Anh Do
Xuemei Wang
P2860
P304
P356
10.1200/JCO.2008.18.1701
P407
P50
P577
2009-02-17T00:00:00Z